Rapport Therapeutics Inc.

This study tests the long-term safety of an experimental drug, RAP-219, in 30 adults with refractory focal epilepsy (seizures that don't respond well to current treatments). Participants must have completed a previous related study. The main goal is to check for side effects, whi…

This study tests an experimental drug, RAP-219, in 333 adults with focal seizures (a type of epilepsy). Participants will take the drug or a placebo for several weeks to see if it safely reduces how often seizures happen. The goal is to find a new treatment option for people whos…

This study tests an experimental drug called RAP-219 for people with bipolar I disorder who are currently having a manic episode (feeling extremely high, energetic, or irritable). About 250 adults will receive either RAP-219 or a placebo to see if the drug safely reduces manic sy…